Cancer and COVID-19: Analysis of Patient Outcomes

Aboueshia, Mohamed; Hussein, Mohammad; Attia, Abdallah S.; Swinford, Aubrey; Miller, Peter; Omar, Mahmoud; Toraih, Eman A.; Saba, Nakhle S.; Safah, Hana; Duchesne, Juan; Kandil, Emad

doi:10.2217/fon-2021-0121

Cited by 43 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, our mean LOS of 11.2 days was likely affected by outlier cases (maximum LOS = 87 days). The median LOS for our hospitalized patients was 6 days and these findings were similar to other studies looking at hospitalizations for this patient population [15,16]. The average LOS for our hospitalized patients without COVID-19 during the same time period was 7.6 days.…”

Section: Discussionsupporting

confidence: 89%

Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center

Manzano

Muthu

Kheder

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose Several studies have confirmed increased mortality among patients with both COVID-19 and cancer. It remains important to continue to report observations of morbidity and mortality from COVID-19 in this vulnerable population. The purpose of this study is to describe the hospitalization characteristics and outcomes of patients with both cancer and COVID-19 admitted to our comprehensive cancer center. Methods This was a descriptive study of the first COVID-19-related hospitalization among adult patients with cancer admitted to our institution. Descriptive statistics were used to summarize patient demographics, clinical as well as hospitalization characteristics. Overall survival (OS) was estimated using the Kaplan-Meier method. Results A total of 212 patients were included in our cohort with a mean age of 59 years. Fifty-four percent of patients had history of solid tumor malignancy and 46% had hematologic malignancies. Eighty-five percent of our cohort had active malignancy. The mean length of stay (LOS) for hospitalization was 11.2 days (median LOS of 6 days). Twenty-five percent had severe disease and 10.8% died during their initial hospitalization. Those who had severe disease had worse survival at the end of the observation period. Conclusions COVID-19 among cancer patients causes significant morbidity and mortality as well as repeat hospitalizations. Continued study of COVID-19 in this vulnerable population is essential in order to better inform evolving treatment algorithms, public health policies, and infection control protocols, especially for institutions caring for patients with cancer.

show abstract

Section: Discussionsupporting

confidence: 89%

Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center

Manzano

Muthu

Kheder

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…It is also shown that mortality in the hospital setting for COVID-19-infected cancer patients is five times greater than the mortality of COVID-19 non-elderly and predisposing-condition-free patients [ 96 , 99 ]. However, in a retrospective cohort [ 100 ], the adverse outcomes were mainly attributed to the comorbidities that cancer patients present with, such as obesity, active smoking and old age. Moreover, although preliminary findings did not manage to support a significant association between recent cytotoxic chemotherapy treatment and adverse COVID-19 outcomes [ 101 ], later studies using larger cohorts demonstrated that cancer patients receiving chemotherapy or chemoradiotherapy had also an increased risk of worse outcomes, especially when the anticancer treatment had been administrated shortly before infection [ 98 ].…”

Section: Covid-19 and Cancermentioning

confidence: 99%

COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment

Liapis

Baritaki

2022

Cancers

View full text Add to dashboard Cite

The COVID-19 pandemic accounts for more than 500 million confirmed infections and over 6 million deaths worldwide in the last 2 years. SARS-CoV-2 causes a highly complex form of inflammation that affects the human organism both acutely and chronically. In the same line, cancer as an inflammation-induced and immune-editing disease appears to cross-react with immune system at different levels including early interactions during carcinogenesis and later cross-talks within the tumor microenvironment. With all that in mind, a reasonable question one might address is whether the SARS-CoV-2 infection and the derived “long lasting inflammatory status” that is frequently observed in patients, might affect the cancer immunosurveillance mechanisms and consequently their risk of developing cancer, as well as the tumor and immune cell behaviors within the inflamed microenvironment. On this context, this review intends to outline and discuss the existing knowledge on SARS-CoV-2-mediated immunomodulation under the prism of changes that might be able to interfere with cancer cell immunoescape and the overall tumor progression and response to conventional therapeutics. Our goal is to highlight a potential interplay between the COVID-19 immunopathology and cancer immune-microenvironment that may pave the way for thorough investigation in the future.

show abstract

“…We identified three studies in the literature that compared the differences in characteristics and outcomes among 5542 COVID-19 infected patients with ( n = 398) and without malignancies ( n = 5144) [ 19 , 20 , 21 ]. Their outcomes are summarized in Table 1 .…”

Section: Covid-19 and Malignancymentioning

confidence: 99%

“…Additionally, patients who received surgery and immunotherapy presented with elevated mortality and increased incidence of severe symptoms, while this was not observed for those under radiotherapy [ 19 ]. Finally, Aboueshia et al detected no difference in mortality rates among patients with cancer who were currently under treatment (active) and those who were not (non-active) [ 21 ].…”

Section: Covid-19 and Malignancymentioning

confidence: 99%

Where Enhanced Recovery after Surgery (ERAS) Protocols Meet the Three Major Current Pandemics: COVID-19, Obesity and Malignancy

Prodromidou

Koulakmanidis

Haidopoulos

et al. 2022

Cancers

View full text Add to dashboard Cite

The outbreak of the SARS-CoV-2 (COVID-19) pandemic has transformed the provision of medical services for both patients that receive care for COVID-19 and for those that need care either for benign diseases, including obesity, or for malignancies, such as gynecological cancer. In this perspective article, we focus on the association among three major worldwide health issues and how ERAS protocols can potentially provide optimal management of patients with obesity and malignancy during the COVID-19 pandemic, with special attention to patients who required surgery for gynecologic oncology. A thorough search of the literature on the respective topics was performed. Patients with malignancy and obesity presented with increased vulnerability to COVID-19 infection. However, the management of their disease should not be withheld. Protective measures should be established to reduce exposure of patients with oncological diseases to SARS-CoV-2 while simultaneously enabling their access to vaccination. Since ERAS protocols have proved to be efficient in many surgical fields, including gynecologic oncology, general surgery, and orthopedics, we strongly believe that ERAS protocols may play a significant role in this effort. The end of the COVID-19 pandemic cannot be accurately predicted. Nevertheless, we have to ensure the appropriate and efficient management of certain groups of patients.

show abstract

Cancer and COVID-19: Analysis of Patient Outcomes

Cited by 43 publications

References 22 publications

Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center

Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center

COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment

Where Enhanced Recovery after Surgery (ERAS) Protocols Meet the Three Major Current Pandemics: COVID-19, Obesity and Malignancy

Contact Info

Product

Resources

About